niacinamide and sb 225002

niacinamide has been researched along with sb 225002 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Devapatla, B; Sharma, A; Woo, S	1

Other Studies

1 other study(ies) available for niacinamide and sb 225002

Article	Year
CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer. PloS one, 2015, Volume: 10, Issue:9 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Ovarian Neoplasms; Phenotype; Phenylurea Compounds; Receptors, Interleukin-8B; Sorafenib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2015

Article

Year

CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.

PloS one, 2015, Volume: 10, Issue:9

Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Ovarian Neoplasms; Phenotype; Phenylurea Compounds; Receptors, Interleukin-8B; Sorafenib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2015